课题基金 / 基金详情

INTERACTION OF DILTIAZEM & VERAPAMIL WITH SIMVASTATIN

INTERACTION OF DILTIAZEM & VERAPAMIL WITH SIMVASTATIN
地尔硫卓的相互作用
批准号：
6265102
负责人：
D CRAIG BRATER
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265102
关键词：
antihypercholesterolemic agent clinical research clinical trial phase I cytochrome P450 diltiazem drug interactions human subject human therapy evaluation pharmacokinetics verapamil

项目摘要

项目成果

D CRAIG BRATER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Simvastatin, like lovastatin is converted to active metabolites by cytochrome P450 3A4 (CYP3A4). We have shown that lovastatin is susceptible to interactions with a commonly used calcium antagonist, diltiazem, that is known to have the capacity to block CYP3A4. Verapamil can similarly block this enzyme. The current study is to quantify the interaction of diltiazem and of verapamil with simvastatin since combinations of either of these calcium antagonists with simvastatin are likely to occur frequently.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diuretics on Response to Torsemide in Patients with Congestive Heart Failure
General Clinical Research Ctr:Pharmacogenetics Core Supp
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
海外基金